NIH is looking for parties interested in collaborative research to further develop the use of Synovial Sarcoma X Breakpoint-2 (SSX-2) Specific Human T-cell Receptors for treating a wide range of cancers:
http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2199
This could greatly benefit some of the synovial sarcoma patients, hopefully…